Council for Innovation Promotion

Dr. Rachel Goode, an executive at a German generic pharmaceutical company, recently argued that “brand-name drug companies are gaming the [U.S.] patent system” by filing duplicative patents meant to block generics manufacturers from entering the market with cheaper copy-cat treatments. But there’s scant evidence to support that claim. Brand-name drugmakers file patents at a rate […]

More than two dozen policymakers recently sent a letter to the U.S. Secretary of Health and Human Services, Xavier Becerra, calling on him to misuse a provision of the Bayh-Dole Act to lower the price of the prostate cancer drug Xtandi. The lawmakers’ request, if Becerra grants it, would chill innovation and disincentivize the launch